AI Data Becomes Sticking Point in Biopharma Dealmaking

Introduction

The integration of artificial intelligence (AI) into drug discovery has transformed the landscape of biopharmaceutical innovation. No longer are traditional wet-lab methods alone sufficient for identifying drug candidates; instead, AI-driven platforms are now a core element in accelerating the identification and development of new therapeutics. However, as global pharmaceutical giants increasingly partner with AI-first biotechs to harness these capabilities, a new and significant challenge has emerged: the question of data ownership and control.

Where and how data is generated within these joint ventures—and who ultimately controls it—has rapidly become a critical headache for dealmakers across the industry. This issue, once viewed as a secondary contractual detail, is now a central concern that can make or break deals and collaborative projects.

The Evolution of Biopharma Partnerships

To appreciate the significance of data in biopharma deals, it’s essential to understand the changing nature of pharmaceutical research. In the past, collaborations were often straightforward: one party provided research, another provided commercial expertise or funding. But the surge in AI capabilities has fundamentally altered this dynamic. AI companies, often data-rich but relatively cash-poor, have become pivotal partners capable of sifting through massive datasets to generate new hypotheses, validate targets, and even predict how molecules might behave in the body. As a result, the intellectual property negotiated in these deals now extends far beyond molecules and patents to include training data, machine learning algorithms, and the unique data streams generated by these systems.

Why Data Is Central to Modern Drug Discovery

AI’s potential to identify therapeutic candidates at unprecedented speed and scale hinges on access to high-quality, diverse data. For pharmaceutical companies, exclusive access to proprietary datasets can mean a pronounced competitive advantage. For AI-driven innovators, the value proposition increasingly centers on their unique, refined datasets and the algorithms trained on them. This makes contractual terms that govern data access, use, and future ownership critically important.

It is no longer just about licensing the right to use a molecule or development pathway; it’s also about controlling datasets derived from human patients, preclinical models, chemical libraries, and even real-world patient outcomes. Depending on how deals are structured, each party may have differing rights to use or commercialize these data in the future, with significant implications for ongoing and future research endeavors.

The Big Questions: Who Owns the Data?

In practice, the sources of friction are many. Does a pharmaceutical partner own the data generated through its clinical trials if those trials are run using a biotech’s AI platform, or does the AI company retain rights to the new data derived from its algorithms’ outputs? Who can use the resulting datasets, and for what purposes? Can a partner use proprietary AI-generated data to develop their own competing products?

These questions are particularly tricky in cases where collaboration generates novel, large-scale datasets—training material that can be used to further enhance AI predictive power, leading to a cycle where data feeds AI advances and vice versa. Negotiating these terms upfront, with contingencies for future technological progress, is now a staple of complex dealmaking in the sector.

Contractual Headaches: Recent Trends and Challenges

Several trends are fueling these disputes:

• Increasing deal complexity: Agreements now often span thousands of pages and must address data issues as a core concern rather than a boilerplate clause.
• Regulatory uncertainty: Evolving privacy laws in key markets like Europe, China, and the United States complicate cross-border data use and sharing.
• Competitive tension: Both sides increasingly view data as a competitive asset, with each party eager to maximize its future value.
• Rapid technological development: The field’s speed means data once considered marginal may become central to future therapies or proprietary AI systems.

As a result, legal experts, dealmakers, and scientists find themselves wrestling with complex scenarios unforeseen in traditional biopharma partnerships.

Real-World Examples

While specifics often remain confidential, public examples abound. Some pharmaceutical companies have opted for “exclusive” deals that grant them sole access to all data generated via collaboration. Others insist on perpetual, royalty-free licenses to use AI-generated insights or data, while AI biotechs often push for shared or retained rights to continue refining their algorithms. In some instances, disagreements over data ownership have surfaced late in the negotiation process, scuttling high-profile deals or provoking expensive renegotiations.

Navigating the New Deal Environment

For dealmakers, this means developing a sophisticated understanding of both technical and legal nuances. Data ownership clauses must now account for the following:

• Definition of “data”: Spelling out exactly what counts as “generated data”—including raw databases, annotated datasets, algorithm outputs, and post-processed insights.
• Access and use rights: Clarifying which party can use which data and for what purposes, both during and after the collaboration.
• Future leveraging: Including terms regarding the use of data to train next-generation AI models, potentially with additional compensation or carve-outs.
• Regulatory compliance: Ensuring that data use conforms to evolving standards for personal and health data privacy, particularly across diverse legal jurisdictions.

The Strategic Stakes

Both Big Pharma and AI-first biotechs recognize that the path to new drugs, patent filings, and market leadership is increasingly dictated by who has data—and what they can do with it. As the boundaries blur between platform and product, collaboration itself becomes a strategic asset. In pursuing these deals, both sides are testing new ways of sharing risk and upside, balancing the protection of proprietary intellectual property against the collective benefits of platform innovation.

Implications for Innovation

While the complexity of these negotiations may seem a brake on progress, others argue it’s a signal of a maturing industry. A new, more sophisticated contract environment may ultimately protect the interests of both sides, providing the clarity needed to enable bolder collaborations and capture AI’s full promise for drug discovery. Still, the process takes time, and dealmakers warn that the rising complexity can slow down partnerships or inflate costs, particularly for smaller AI firms with less deal-making experience.

Conclusion: Navigating the Future

In the years ahead, expect even greater focus on contractual frameworks that explicitly address data stewardship, ownership, and future application. The stakes are high: in an industry where time-to-market can mean billions of dollars and immense impact on patient lives, every detail matters. How these challenges are navigated will shape the pace of drug innovation for years to come, especially as AI-driven platforms continue to evolve.

For now, data has shifted from being a background resource to a front-and-center concern—one that the entire biopharmaceutical sector must grapple with in both strategic and operational terms.

Source: BioSpace